Vitrolife

Second quarter

• Sales of SEK 857 (871) million, a decrease of 1% in local currencies and 2% decrease in SEK. Organic growth in local currencies excluding exited business of the NACE and GDPX product lines was 1%.
• Sales* per region were +1% in EMEA, +1% in Americas and -1% in APAC.
• Sales* per product group were +3% in Consumables, +1% in Technologies and -2% in Genetics.
• Gross margin increased to 60.3% (58.0).
• Earnings before depreciation and amortisation (EBITDA) amounted to SEK 295 (243) million, resulting in an EBITDA margin of 34.4% (27.8). In addition, our EBITDA was positively affected by one-time effects of 13 MSEK, primarily driven by a VAT accrual reversal and also a positive currency revaluation effect of 8 (-5) MSEK in operating expenses.
• Net income amounted to SEK 129 (100) million, resulting in earnings per share of SEK 0.95 (0.74).
• Operating cash flow amounted to SEK 140 (151) million.

First half year

• Sales of SEK 1,664 (1,714) million, a growth of 2% in local currencies and a 3% decrease in SEK, due to a significant currency impact of -5%. Organic growth* was 3%.
• Sales* per region were 0% in EMEA, +6% in Americas and +3% in APAC.
• Sales* per product group were +6% in Consumables, +6% in Technologies and -1% in Genetics.
• Gross margin increased to 60.1% (57.7).
• Earnings before depreciation and amortisation (EBITDA) increased to SEK 546 (500) million, resulting in an EBITDA margin of 32.8% (29.2).
• Net income was SEK 230 (199) million, resulting in earnings per share of SEK 1.69 (1.48).
• Operating cash flow amounted to SEK 312 million (220).

* In local currency and excluding exited business of the NACE and GDPX product lines